Menarini Expands In Cancer With Radius Drug Deal
Elacestrant Is An Oral SERD In Phase III For Breast Cancer
Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.
